Riskpilot← Back to searchSign inGet full accessCeremedy ApS
APSActiveCVR 39797712Amaliegade 6, 2. tvResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20189 employees
Revenue 2025
DKK -6M
-33% vs 2024
EBITDA margin
200.7%
+9% vs 2024
Equity ratio
87.2%
Financial strength
Net profit 2025
DKK -10M
+5% vs 2024
| Revenue | DKK -6M | -33% |
| EBITDA | DKK -12M | +9% |
| Net profit | DKK -10M | +5% |
| Total assets | DKK 7,6M | +23% |
| Equity | DKK 6,6M | +35% |
| Employees | 9 | — |
Legal name
Ceremedy ApS
CVR number
39797712
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20. august 2018
Share capital
DKK 50.000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af hele direktionen i forening eller af en direktør alene.
Company purpose
Selskabets formål er at udføre aktiviteter relaterede til forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler til diagnosticering, behandling og/eller forebyggelse af narkolepsi, narkolepsi-relaterede neurologiske sygdomme, og andre med lægemiddeludvikling relaterede aktiviteter, samt at yde konsulentydelser til selskaber, som er beskæftigede indenfor selskabets hovedformål.
Address
Amaliegade 6, 2. tv
Phone
+4551594565
Email
cth@ceremedy.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -1.168 | -275 | -819 | -726 | -5.722 | -8.916 | -5.969 |
| Staff expenses | -0 | -0 | -0 | -0 | -3.042 | -4.296 | -6.011 |
| EBITDA | -1.168 | -275 | -819 | -726 | -8.764 | -13.212 | -11.980 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -277 | -496 |
| EBIT | -1.168 | -275 | -819 | -726 | -8.764 | -13.489 | -12.477 |
| Net financials | -191 | -183 | -193 | -207 | -123 | -9 | 44 |
| Profit before tax | -1.359 | -458 | -1.012 | -933 | -8.888 | -13.498 | -12.432 |
| Tax | -213 | -45 | -0 | -0 | -1.619 | -2.902 | -2.387 |
| Net profit | -1.145 | -412 | -1.012 | -933 | -7.269 | -10.596 | -10.046 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 1.204 | 879 | 367 | 129 | 5.341 | 6.195 | 7.609 |
| Equity | -1.095 | -1.508 | -2.519 | -3.452 | 159 | 4.899 | 6.635 |
| Long-term debt | 2.187 | 2.362 | 2.551 | 0 | 0 | 0 | 0 |
| Short-term debt | 112 | 25 | 336 | 3.581 | 5.183 | 1.297 | 974 |
| Total debt | 2.299 | 2.387 | 2.886 | 3.581 | 5.183 | 1.297 | 974 |
EBITDA margin
-1198046300.0%
This company
15.8%
Market median
-7582571619% vs market
20192025
Equity ratio
87.2%
This company
38.2%
Market median
+128% vs market
20192025
Return on equity
-151.4%
This company
18.4%
Market median
-923% vs market
20192025
Net profit margin
-1004571400.0%
This company
8.1%
Market median
-12402116149% vs market
20192025
Asset turnover
-0.78×
This company
1.12×
Market median
-170% vs market
20192025
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-20 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CT Management | Management | 2023 | — | — |
BR Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ceremedy Holdings ApS | Company | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Ceremedy ApS Board members of Ceremedy ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Casper Tind Hansen | Management | 0 companies |
| Birgitte Rahbek Kornum | Chief Executive Officer | 0 companies |